Sixty seconds on . . . solanezumabBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6389 (Published 29 November 2016) Cite this as: BMJ 2016;355:i6389
- Nigel Hawkes
More bad news on drugs for Alzheimer’s disease?
Yes, another drug has failed in phase III trials. This one is solanezumab, whose demise was a three act drama that’s finally seen the curtain fall.1 2 3
Was that a surprise?
Not really. Alzheimer’s disease is the graveyard of drug discovery. One study found that of 244 compounds tested between 2000 and 2014 only one was ever licensed, a failure rate of 99.6%.4
That implies everybody’s doing something wrong
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial